Oral Insulin Delivery: Overcoming Gastrointestinal Barriers for Needle-Free Diabetes Management

Alexander James Tremblay [1*], Dr. Sophia Elaine McAlliste [2]
[1] PhD, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
[2] PhD, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

* Corresponding Author: **Alexander James Tremblay**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 04
July- August 2024
Received: 02-05-2024
Accepted: 04-06-2024
Published: 06-07-2024
Page No: 01-14

Abstract
Diabetes mellitus represents a global health challenge affecting over 500 million individuals worldwide, with insulin remaining the cornerstone of glycemic control for type 1 diabetes and advanced type 2 diabetes. Despite its therapeutic efficacy, subcutaneous insulin administration faces significant limitations including patient non-compliance, injection-associated pain, needle phobia, and failure to replicate physiological insulin secretion patterns. Oral insulin delivery has emerged as a transformative alternative that promises needle-free administration, improved patient adherence, and restoration of hepatoportal insulin gradients mimicking endogenous secretion. However, the gastrointestinal tract presents formidable physiological barriers including harsh gastric acidity, proteolytic enzyme degradation, mucus layer impedance, and limited intestinal epithelial permeability. This comprehensive review examines the pathophysiology of gastrointestinal barriers, advanced pharmaceutical strategies for oral insulin formulation, emerging nanotechnology-based delivery platforms, permeation enhancement mechanisms, targeted intestinal absorption strategies, and clinical translation progress. We critically evaluate encapsulation technologies, pH-responsive polymers, protease inhibitors, mucoadhesive systems, nanoparticle carriers, cell-penetrating peptides, and receptor-mediated transport exploitation. Furthermore, we discuss pharmacokinetic optimization, bioavailability enhancement, safety considerations, regulatory pathways, and future directions toward achieving clinically viable oral insulin therapeutics for transforming diabetes management.

DOI:

Keywords: Oral Insulin, Drug Delivery, Diabetes Mellitus, Gastrointestinal Barriers, Nanoparticles, Bioavailability, Permeation Enhancers, Needle-Free Administration

1. Introduction

1.1. Epidemiology and Burden of Diabetes Mellitus

Diabetes mellitus constitutes one of the most pressing global health crises, with prevalence projections indicating approximately 783 million affected individuals by 2045 [1]. Type 1 diabetes, characterized by autoimmune destruction of pancreatic beta cells, necessitates lifelong exogenous insulin replacement for survival. Type 2 diabetes, accounting for 90-95% of cases, often progresses to insulin dependence as beta cell function declines despite initial responsiveness to oral hypoglycemic agents [2]. The chronic hyperglycemia associated with inadequate glycemic control leads to devastating microvascular complications including retinopathy, nephropathy, and neuropathy, as well as macrovascular sequelae such as cardiovascular disease, stroke, and peripheral arterial disease [3].

The economic burden of diabetes encompasses direct medical costs exceeding $760 billion annually worldwide, with substantial indirect costs from productivity losses, disability, and premature mortality [4]. Quality of life impairment extends beyond physical complications to include psychological distress, anxiety regarding hypoglycemia, and social stigma associated with visible insulin administration. Current treatment paradigms require intensive insulin regimens involving multiple daily injections or continuous subcutaneous insulin infusion via pump devices, both of which impose significant burdens on patients and healthcare systems.

1.2. Limitations of Current Insulin Delivery Methods

Subcutaneous insulin injection, introduced clinically in the 1920s, remains the standard route despite nearly a century of technological advances [5]. This delivery method suffers from multiple fundamental limitations that compromise therapeutic outcomes and patient well-being. The peripheral route of administration creates supraphysiological systemic insulin concentrations while failing to achieve appropriate hepatic insulin levels, disrupting the normal hepatoportal insulin gradient essential for optimal hepatic glucose metabolism [6]. This aberrant insulin distribution contributes to suboptimal glycemic control, peripheral hyperinsulinemia, weight gain, and increased hypoglycemia risk.

Patient compliance represents a major clinical challenge, with injection burden directly correlating with treatment non-adherence [7]. Needle phobia affects approximately 20-30% of adults and up to 63% of children, creating psychological barriers to optimal diabetes management. Injection site complications including lipohypertrophy, lipoatrophy, pain, bruising, and infection further reduce quality of life and treatment satisfaction. The requirement for cold chain storage and transportation infrastructure limits insulin accessibility in resource-limited settings, contributing to health disparities [8].

Pharmacokinetic limitations of subcutaneous delivery include delayed absorption kinetics that poorly match postprandial glucose excursions, inter-individual and intra-individual variability in absorption rates, and inability to rapidly terminate insulin action during hypoglycemic episodes [9]. These factors necessitate careful timing of meals relative to injections, lifestyle restrictions, and continuous glucose monitoring to minimize glycemic variability. The cumulative burden of these limitations underscores the urgent need for alternative insulin delivery routes that improve therapeutic efficacy while enhancing patient acceptance and adherence.

1.3. Physiological Advantages of Oral Insulin Delivery

Oral insulin delivery offers compelling physiological advantages that extend beyond mere convenience [10]. Following oral administration and intestinal absorption, insulin undergoes first-pass hepatic metabolism, replicating the physiological hepatoportal insulin gradient present in healthy individuals. This preferential hepatic exposure optimizes hepatic glucose uptake, glycogen synthesis, and suppression of hepatic glucose production while reducing peripheral hyperinsulinemia [11]. Restoration of physiological insulin distribution patterns may improve glycemic control, reduce hypoglycemia incidence, minimize weight gain, and potentially prevent long-term microvascular complications.

The enteral route eliminates injection-related complications, improves cosmetic outcomes, reduces sharps waste and disposal challenges, and removes psychological barriers associated with needles [12]. Enhanced patient convenience and acceptance translate to improved treatment adherence, particularly in pediatric populations, elderly patients with dexterity limitations, and individuals with needle phobia. Oral formulations enable easier dose titration, self-management, and integration into daily routines compared to injection regimens.

From a pharmaceutical perspective, oral delivery potentially reduces manufacturing costs, simplifies distribution logistics by eliminating cold chain requirements for certain formulations, and facilitates global access in low-resource settings [13]. The non-invasive nature of oral administration enables more frequent dosing if needed without additional patient burden, allowing flexible treatment regimens tailored to individual metabolic needs and lifestyle patterns. These multifaceted advantages provide strong rationale for sustained research investment despite the substantial technological challenges involved in achieving clinically viable oral insulin delivery systems.

2. Gastrointestinal Barriers to Oral Insulin Absorption



Fig 1: Major Gastrointestinal Barriers to Oral Insulin Absorption

2.1. Acidic Gastric Environment and pH Instability

The stomach presents the first major barrier to oral insulin delivery through its highly acidic environment, with pH values typically ranging from 1.5 to 3.5 in the fasted state [14]. This extreme acidity serves protective antimicrobial functions and initiates protein digestion but creates hostile conditions for protein therapeutics. Insulin, a 51-amino acid polypeptide comprising two chains linked by disulfide bonds, exhibits pH-dependent structural stability with optimal conformity between pH 4 and 7 [15]. Exposure to gastric acid induces rapid denaturation, unfolding, and aggregation of insulin molecules, destroying the native tertiary structure essential for biological activity.

Acid-catalyzed hydrolysis of peptide bonds, particularly those involving aspartic acid residues, leads to fragmentation of the insulin molecule [16]. The kinetics of acid-mediated degradation demonstrate first-order processes with half-lives of minutes under gastric conditions, resulting in nearly complete loss of bioactivity before reaching the intestinal absorption sites. Additionally, gastric pH fluctuations associated with fed versus fasted states, circadian rhythms, and individual variations in gastric acid secretion introduce substantial inter-individual and intra-individual variability in insulin stability.

Protective strategies against gastric acid-induced degradation include enteric coating technologies that prevent insulin release until reaching the higher pH environment of the small intestine, buffering systems that locally neutralize gastric acid, and chemical modifications that enhance acid stability [17]. Nanoencapsulation within acid-resistant polymeric matrices provides physical protection while maintaining insulin in its native conformation. However, these protective measures must be balanced against the need for eventual insulin release and absorption, creating complex formulation optimization challenges.

2.2. Enzymatic Degradation in the Gastrointestinal Tract

Beyond acid-mediated degradation, insulin faces intensive enzymatic assault throughout the gastrointestinal tract [18]. The stomach contains pepsin, an aspartic protease optimally active at acidic pH, which initiates protein hydrolysis by preferentially cleaving peptide bonds between hydrophobic amino acids. The small intestine contains a diverse arsenal of pancreatic and brush border proteases including trypsin, chymotrypsin, elastase, carboxypeptidases, and aminopeptidases, collectively capable of rapidly degrading intact proteins to amino acids and small peptides [19].

Trypsin and chymotrypsin exhibit particularly high activity against insulin, with specific cleavage sites at lysine, arginine (trypsin) and aromatic amino acid residues (chymotrypsin) throughout the insulin molecule [20]. Brush border peptidases embedded in the intestinal epithelial surface provide an additional enzymatic barrier immediately adjacent to absorption sites. The combined proteolytic activity in the intestinal lumen results in insulin half-lives of only 5-10 minutes, with greater than 95% degradation occurring before potential absorption.

Protease inhibition strategies include co-administration of protease inhibitors such as aprotinin, bowman-birk inhibitor, camostat mesilate, or nafamostat mesylate. Alternatively, enzyme-resistant insulin analogs incorporating non-natural amino acids, D-amino acids, or modified backbone structures can resist proteolytic cleavage while maintaining receptor binding and biological activity. Nanoparticle encapsulation physically shields insulin from enzymatic access, with release kinetics designed to occur after transport across the epithelial barrier. However, protease inhibitor approaches raise safety concerns regarding interference with physiological digestion and potential systemic effects if absorbed.

2.3. Intestinal Mucus Layer and Epithelial Barriers

The intestinal mucus layer constitutes a complex hydrogel network comprising mucin glycoproteins, lipids, cellular debris, commensal bacteria, and antimicrobial peptides. This viscoelastic barrier, measuring 50-800 micrometers in thickness depending on intestinal region, serves protective functions against pathogens, toxins, and mechanical stress while regulating nutrient absorption. The mucus gel exhibits size-selective permeability, with mesh spacing of approximately 100-500 nanometers that efficiently traps particles and macromolecules while allowing passage of water, ions, and small molecules.

Mucus turnover occurs continuously through goblet cell secretion and sloughing of the luminal mucus layer, creating a dynamic barrier that must be penetrated within limited timeframes for successful drug absorption. The mucus pH gradient increases from approximately 5.5 at the intestinal surface to 7.4 at the epithelial interface, influencing charge interactions with delivery systems. Electrostatic interactions between negatively charged mucin carboxylate and sulfate groups and cationic delivery vehicles result in mucoadhesion that can either facilitate prolonged residence time or impede epithelial access depending on formulation design.

Strategies to overcome mucus barriers include mucoadhesive systems that attach to the mucus layer for extended release, mucolytic agents such as N-acetylcysteine that disrupt disulfide bonds in mucin proteins, and mucopenetrating particles with hydrophilic, neutrally charged surfaces that slip through mucus pores. Size optimization of nanocarriers to dimensions below mucus mesh spacing (< 200 nm) and surface modification with polyethylene glycol or other hydrophilic polymers enhance mucus penetration. Recent approaches employ enzyme-functionalized nanoparticles that locally degrade mucus components to create transit pathways.

2.4. Intestinal Epithelial Permeability Limitations

The intestinal epithelium represents the ultimate barrier to oral insulin absorption, comprising a polarized monolayer of enterocytes interconnected by tight junction complexes. This selectively permeable barrier facilitates nutrient absorption while excluding pathogens, toxins, and macromolecules. The epithelial permeability to compounds depends critically on molecular weight, with the cutoff for paracellular transport approximating 500-1000 Daltons—far below insulin's molecular weight of 5808 Daltons.

Transcellular transport through enterocytes requires either passive diffusion across lipid membranes (favorable for small, lipophilic molecules but not hydrophilic peptides like insulin) or active/receptor-mediated transport mechanisms. The apical enterocyte membrane exhibits minimal fluid-phase endocytosis in mature cells, limiting opportunities for insulin internalization. Basolateral export mechanisms may represent additional barriers even for successfully internalized insulin. The rapid turnover of intestinal epithelial

cells (3-5 day lifespan) creates a perpetually renewing barrier with variable absorption characteristics along the crypt-villus axis.

Tight junction complexes comprising claudins, occludins, and zonula occludens proteins create the paracellular seal that restricts macromolecule passage. These dynamic structures exhibit limited physiological permeability modulation in response to nutrients, hormones, and inflammatory signals. Pathological tight junction opening occurs in intestinal diseases but represents an unsafe strategy for therapeutic exploitation. Viable approaches to enhance epithelial permeability include absorption enhancers that transiently and reversibly increase paracellular permeability, transcytosis-inducing agents, and receptor-mediated transport ligands discussed in subsequent sections.

Table 1: Physiological Barriers to Oral Insulin Delivery in the Gastrointestinal Tract

Barrier	Location	Mechanism	Impact on Insulin	Quantitative Effect
Gastric acid	Stomach	pH 1.5-3.5, acid-catalyzed hydrolysis	Protein denaturation, aggregation, fragmentation	t½ < 5 min, >90% degradation
Pepsin	Stomach	Aspartic protease, pH 1-4 optimal	Peptide bond cleavage at hydrophobic residues	50-70% degradation
Pancreatic proteases	Small intestine	Trypsin, chymotrypsin, elastase	Rapid protein hydrolysis	t½ 5-10 min, >95% degradation
Brush border peptidases	Intestinal epithelium	Aminopeptidases, carboxypeptidases	Terminal degradation at absorption site	80-90% remaining insulin cleaved
Mucus layer	Small intestine	Viscoelastic gel barrier, 50-800 µm	Physical entrapment, size exclusion	>90% particle retention
Tight junctions	Epithelial barrier	Claudins, occludins, ZO proteins	Paracellular seal, MW cutoff ~500 Da	>99.9% exclusion of insulin (5808 Da)
Epithelial membrane	Enterocytes	Lipid bilayer, low endocytosis	Hydrophilic macromolecule exclusion	<0.1% transcellular passage
First-pass metabolism	Liver	Insulin-degrading enzyme	Hepatic insulin clearance	50-80% first-pass extraction

Table 2: Formulation Strategies for Oral Insulin Delivery Systems

Strategy	Approach	Mechanism	Examples	Advantages	Limitations
Enteric coating	pH-responsive polymers	Acid resistance, intestinal release	Eudragit, HPMCP, CAP	Gastric protection, targeted release	Burst release, incomplete protection
Protease inhibitors	Enzyme inhibition	Competitive/irreversible inhibition	Aprotinin, camostat, bowman-birk	Reduced enzymatic degradation	Toxicity, digestive interference
Absorption enhancers	Permeability increase	Tight junction modulation	SNAC, caprate, chitosan	Enhanced epithelial transport	Safety concerns, transient effect
Mucoadhesive systems	Prolonged residence	Electrostatic/H-bonding to mucus	Chitosan, carbomer, alginate	Extended contact time	Mucus entrapment
Nanoparticle carriers	Encapsulation	Physical protection, targeted delivery	PLGA, alginate, liposomes	Multi-barrier protection	Scalability, stability
Chemical modification	PEGylation, acylation	Enhanced stability, permeability	PEG-insulin, fatty acid conjugates	Improved PK, reduced immunogenicity	Altered activity, cost
Cell-penetrating peptides	Active transport	Membrane translocation	TAT, penetratin, RGD	Epithelial penetration	Limited specificity
Receptor targeting	Ligand-mediated uptake	Transcytosis exploitation	Vitamin B12, transferrin, FcRn	Specific transport pathways	Receptor saturation, competition



Fig 2: Key Formulation Strategies to Overcome Gastrointestinal Barriers

3. Pharmaceutical Strategies for Oral Insulin Formulation

3.1. Enteric Coating and pH-Responsive Polymer Systems

Enteric coating technology represents the foundational approach for protecting insulin from gastric degradation while enabling release in the higher pH environment of the small intestine. pH-responsive polymers such as methacrylic acid copolymers (Eudragit series), hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and polyvinyl acetate phthalate remain insoluble below pH 5-5.5 but undergo rapid dissolution at pH 6-7, corresponding to duodenal and jejunal conditions. These materials form protective coatings around insulin-containing cores, preventing premature drug release while facilitating site-specific delivery.

Advanced enteric systems employ multi-layered coatings with differential pH dissolution thresholds to achieve sequential release profiles or target specific intestinal regions. Layer-by-layer deposition techniques enable precise control of coating thickness, composition, and dissolution kinetics. Incorporation of plasticizers, pore-formers, and coating thickness optimization modulates release rates to prevent burst release while ensuring complete insulin liberation. However, enteric coatings alone cannot address enzymatic degradation or epithelial permeability barriers, necessitating combination with complementary strategies.

Novel pH-responsive hydrogel systems exhibit swelling-dependent drug release, with insulin physically entrapped in polymer networks that expand dramatically upon pH increase. These systems provide buffering capacity that protects insulin during the transition from gastric to intestinal environments. Smart polymers responsive to multiple stimuli (pH, temperature, enzymes) enable more sophisticated release control. Challenges include inter-individual variability in gastrointestinal pH, food effects that alter pH profiles, and the need for rapid dissolution kinetics compatible with intestinal transit times of 3-4 hours.

3.2. Protease Inhibitor Co-Administration

Co-formulation of insulin with protease inhibitors aims to create a local environment of reduced enzymatic activity, prolonging insulin stability in the intestinal lumen. Aprotinin, a broad-spectrum serine protease inhibitor derived from bovine lung, demonstrates efficacy in reducing insulin degradation but raises safety concerns regarding allergic reactions and potential systemic effects. Bowman-Birk inhibitor from soybeans and camostat mesilate provide alternative protease inhibition with improved safety profiles but variable effectiveness.

The optimal protease inhibitor strategy requires high local concentrations at absorption sites while minimizing systemic exposure to avoid interference with physiological digestion and potential toxicological effects. Formulation approaches include co-encapsulation with insulin in protective carriers, separate but simultaneous administration to achieve temporal overlap, and chemical conjugation to insulin molecules or carrier materials. However, protease inhibitor approaches face regulatory scrutiny regarding long-term safety, potential for antinutritional effects, and immunogenicity concerns.

Alternative strategies employ enzyme-resistant insulin analogs incorporating non-natural amino acids, retro-inverso sequences, or cyclized structures that resist proteolytic cleavage while maintaining receptor binding. These approaches eliminate the need for protease inhibitor co-administration but require extensive development of novel insulin molecules with preserved biological activity. Hybrid systems combining partial enzyme resistance with limited protease inhibition may achieve optimal protection with minimal safety concerns.

3.3. Permeation Enhancers and Tight Junction Modulators

Absorption enhancers transiently increase intestinal epithelial permeability through various mechanisms including tight junction modulation, membrane fluidization, or active transport stimulation. Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), the absorption enhancer employed in the FDA-approved oral semaglutide formulation, locally increases gastric pH and facilitates transcellular absorption through transient membrane perturbation. Medium-chain fatty acids including sodium caprate open tight junctions reversibly by inducing cytoskeletal contraction and claudin redistribution.

Chitosan, a cationic polysaccharide, enhances permeability through multiple mechanisms including mucoadhesion, tight junction opening via interactions with zonula occludens proteins, and membrane destabilization. Other enhancers include bile salts, phospholipids, chelating agents such as EDTA, and surfactants. The ideal absorption enhancer exhibits high potency at low concentrations, rapid and reversible action, localized effect without systemic absorption, and excellent safety profile with no mucosal damage or sensitization upon repeated exposure.

Safety evaluation of permeation enhancers requires demonstration of complete and rapid reversibility of permeability changes, absence of morphological damage to the intestinal epithelium, and lack of increased susceptibility to pathogen translocation or toxin absorption. Chronic administration studies must evaluate potential for cumulative mucosal injury, inflammatory responses, or alterations in intestinal microbiome composition. Regulatory acceptance demands robust safety data and clear understanding of mechanism of action. Recent advances focus on targeted delivery of enhancers co-formulated with insulin to minimize exposure duration and intestinal surface area affected.

3.4. Chemical Modification and Insulin Analogs

Chemical modification of insulin to enhance oral bioavailability represents an alternative to formulation-based approaches. PEGylation, the covalent attachment of polyethylene glycol chains to insulin, increases molecular size, reduces enzymatic degradation, decreases renal clearance, and may enhance intestinal permeability through altered physicochemical properties. Site-specific PEGylation at defined positions preserves receptor binding while improving pharmacokinetic properties. However, PEGylation reduces specific activity per unit mass and raises manufacturing complexity and cost.

Fatty acid acylation, exemplified by insulin degludec and insulin detemir for subcutaneous use, creates insulin analogs with enhanced self-association and albumin binding. Adaptation of this technology for oral delivery involves optimizing acyl chain length and attachment position to achieve intestinal absorption while maintaining biological activity. Lipidization enhances membrane permeability but may impair water solubility unless carefully balanced. Other chemical modifications include glycosylation, cyclization, and incorporation of unnatural amino acids with enhanced

proteolytic resistance.

Prodrug strategies involve reversible chemical derivatization that masks insulin's peptide character during transit through degradative environments, with bioconversion to active insulin occurring after absorption or in target tissues. Approaches include ester or amide linkages cleaved by intestinal esterases or systemic enzymes. The prodrug must exhibit sufficient stability during gastrointestinal transit while enabling efficient conversion to active drug. Challenges include identifying appropriate cleavage mechanisms, optimizing prodrug physicochemical properties, and ensuring metabolite safety.

4. Nanotechnology-Based Delivery Platforms



Fig 3: Nanotechnology-Based Platforms for Oral Insulin Delivery

4.1. Polymeric Nanoparticles and Microparticles

Polymeric nanoparticles offer versatile platforms for oral insulin delivery through encapsulation within biodegradable, biocompatible polymer matrices. Poly (lactic-co-glycolic acid) (PLGA) represents the most extensively studied polymer, offering FDA approval for other applications, tunable degradation kinetics through copolymer ratio adjustment, and protection of encapsulated insulin from enzymatic degradation. PLGA nanoparticles can be surface-modified with targeting ligands, permeation enhancers, or mucoadhesive moieties to optimize performance.

Preparation methods including emulsion-solvent evaporation, nanoprecipitation, and spray drying enable control of particle size, morphology, drug loading, and release kinetics. Insulin stability during harsh manufacturing processes represents a significant challenge, requiring optimization of organic solvents, pH, temperature, and mechanical stress. Encapsulation efficiency and loading capacity trade-offs with particle size and release properties necessitate careful formulation development. Surface charge, hydrophobicity, and targeting ligand density critically influence mucus penetration, cellular uptake, and biodistribution.

Natural polymers including chitosan, alginate, dextran, and albumin provide alternative materials with excellent biocompatibility and diverse functional properties. Chitosan nanoparticles combine encapsulation with intrinsic absorption enhancement through mucoadhesion and tight junction opening. Alginate particles cross-linked with calcium or zinc ions protect insulin while enabling pH-triggered release. Layer-by-layer assembly of oppositely charged polymers creates multilayered nanoparticles with sophisticated functionality. However, batch-to-batch variability, scalability limitations, and stability challenges during storage require addressing for clinical translation.

4.2. Lipid-Based Nanocarriers

Lipid-based delivery systems including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and self-emulsifying drug delivery systems exploit lipid biocompatibility and diversity. Liposomes, comprising phospholipid bilayers enclosing aqueous cores, encapsulate hydrophilic insulin while the lipid membrane provides protection from enzymatic degradation. Surface modification with polyethylene glycol (PEGylation) reduces opsonization and enhances stability, while incorporation of charged lipids or targeting ligands directs cellular interactions.

Solid lipid nanoparticles composed of physiological lipids (triglycerides, fatty acids, waxes) solidified at body temperature offer advantages of improved stability, controlled release, and ease of large-scale production compared to liposomes. Nanostructured lipid carriers incorporating liquid lipids within solid lipid matrices provide enhanced drug loading capacity and reduced drug expulsion during storage. These systems can facilitate lymphatic absorption, bypassing first-pass hepatic metabolism, although this may diminish the physiological advantages of hepatoportal insulin delivery.

Self-emulsifying drug delivery systems are isotropic mixtures of oils, surfactants, and co-solvents that spontaneously form fine emulsions upon contact with gastrointestinal fluids. These systems enhance solubility and absorption of lipophilic drugs but require adaptation for hydrophilic insulin delivery through co-formulation

strategies or chemical modification. Challenges common to lipid carriers include potential for oxidation and rancidity, temperature-sensitive stability, and limited insulin loading capacity. However, their excellent safety profiles and established regulatory precedents facilitate clinical development.

4.3. Inorganic and Hybrid Nanoparticle Systems

Inorganic nanoparticles including silica, gold, calcium phosphate, and layered double hydroxides offer unique properties for oral insulin delivery. Mesoporous silica nanoparticles provide high surface area, tunable pore sizes (2-50 nm), surface functionalization opportunities, and excellent physical stability. Insulin loading within mesopores protects against enzymatic degradation while controlled release occurs through diffusion or stimulus-responsive gatekeepers. Surface modification with polymers or lipids enhances biocompatibility and intestinal uptake.

Gold nanoparticles enable precise size control, straightforward surface functionalization through thiol chemistry, and potential for imaging or photothermal applications. However, concerns regarding long-term accumulation and biodegradability limit enthusiasm for gold nanoparticles in chronic disease applications like diabetes. Calcium phosphate nanoparticles offer excellent biocompatibility, biodegradability to physiological calcium and phosphate ions, and pH-responsive dissolution that protects insulin in acidic environments while releasing cargo at intestinal pH.

Hybrid systems combining organic and inorganic components leverage complementary advantages. Core-shell structures with inorganic cores and polymer shells, or vice versa, provide multifunctional capabilities including sequential barrier protection, staged release, and multiple targeting modalities. Metal-organic frameworks represent an emerging class of highly porous crystalline materials with ultrahigh surface areas and tunable pore structures. However, translation of inorganic and hybrid systems faces regulatory uncertainties regarding safety evaluation and approval pathways for novel materials without established use in oral pharmaceuticals.

4.4. Cell-Derived and Biomimetic Nanocarriers

Cell-derived systems including exosomes and membrane vesicles from various cell types offer inherent biocompatibility and natural targeting properties. Milk-derived exosomes loaded with insulin exploit existing oral administration routes and demonstrate stability in gastrointestinal conditions. Plant-derived nanovesicles from edible sources provide low-cost, scalable alternatives with minimal immunogenicity concerns. However, challenges include limited loading capacity, difficulty in large-scale production with consistent properties, and incomplete understanding of targeting mechanisms and safety upon chronic administration.

Biomimetic systems coat synthetic nanoparticles with cell membranes to impart biological functions while maintaining synthetic core advantages. Red blood cell membrane-coated nanoparticles demonstrate prolonged circulation and reduced immune recognition. Epithelial cell membrane coating may enhance intestinal absorption through exploitation of endogenous transport mechanisms. These sophisticated systems require complex preparation procedures and face questions regarding stability, reproducibility, and regulatory classification. Future development may focus on simplified biomimetic approaches that capture key functional advantages without full complexity.

Table 3: Nanotechnology Platforms for Oral Insulin Delivery

Platform	Composition	Size Range	Drug Loading	Key Advantages	Main Challenges	Bioavailability (Preclinical)
PLGA nanoparticles	Poly (lactic-co-glycolic acid)	100-500 nm	5-20%	Biodegradable, FDA-approved, tunable release	Manufacturing complexity, stability	5-15%
Chitosan nanoparticles	Cationic polysaccharide	50-300 nm	10-30%	Mucoadhesive, permeation enhancement	Batch variability, scale-up	8-20%
Liposomes	Phospholipid bilayers	100-500 nm	3-15%	Biocompatible, cell membrane-like	Instability, leakage	3-10%
Solid lipid nanoparticles	Triglycerides, fatty acids	50-400 nm	5-25%	Stable, scalable production	Limited loading, drug expulsion	6-12%
Mesoporous silica	SiO2 with ordered pores	50-300 nm	15-40%	High loading, tunable pores, stable	Biodegradation concerns	10-18%
Alginate beads	Calcium cross-linked alginate	200-800 µm	20-40%	Simple preparation, pH-responsive	Large size, slow release	4-12%
Layer-by-layer particles	Alternating polyelectrolytes	100-400 nm	10-30%	Precise control, multifunctional	Complex preparation	7-15%
Exosome-based	Natural cell vesicles	50-150 nm	5-15%	Natural biocompatibility, targeting	Production scalability	6-14%

5. Mechanisms of Intestinal Absorption Enhancement

5.1. Paracellular Transport Enhancement

The paracellular pathway between adjacent epithelial cells, normally sealed by tight junction complexes, represents a potential route for insulin absorption if permeability can be transiently and safely enhanced. Tight junctions comprise claudin family proteins that form strand-like structures determining pore size and charge selectivity, occludin and junctional adhesion molecules providing structural support, and cytoplasmic zonula occludens proteins linking transmembrane proteins to the actin cytoskeleton. Various agents modulate tight junction permeability through mechanisms including calcium chelation, protein kinase C activation, myosin light chain kinase stimulation, and direct interactions with tight junction proteins.

Chitosan enhances paracellular permeability through

multiple mechanisms: electrostatic interactions between cationic chitosan and anionic cell membranes, redistribution of ZO-1 and occludin from tight junctions, and cytoskeletal rearrangement. The extent of tight junction opening depends on chitosan concentration, molecular weight, degree of deacetylation, and exposure time. Reversibility is critical for safety, with complete restoration of barrier function required within 2-4 hours post-exposure. Medium-chain fatty acids induce contraction of the perijunctional actomyosin ring through activation of protein kinase C, transiently opening tight junctions through mechanical forces.

Safety considerations for paracellular permeation enhancement include potential for increased translocation of bacteria, toxins, and antigens across the epithelium, risk of inducing or exacerbating intestinal inflammation, and concerns regarding effects on absorption of other medications. Localized delivery systems that confine enhancer action to limited intestinal segments for short durations minimize these risks. Biomarkers of tight junction integrity including transepithelial electrical resistance, permeability to marker molecules, and histological examination of tight junction morphology are essential for preclinical and clinical safety evaluation.

5.2. Transcellular and Receptor-Mediated Transport

Transcellular transport through enterocytes offers an alternative absorption route that avoids tight junction manipulation. Receptor-mediated transcytosis exploits physiological transport mechanisms for macromolecules including vitamin B12-intrinsic factor, transferrin, immunoglobulin G, and various peptide hormones. The vitamin B12 receptor (cubilin/amnionless complex) expressed on ileal enterocytes facilitates transcytosis of cobalamin-intrinsic factor complexes; conjugation of insulin to vitamin B12 or intrinsic factor enables exploitation of this pathway for oral delivery.

The neonatal Fc receptor (FcRn), responsible for IgG transcytosis and protection from degradation, represents another promising target for oral insulin delivery. Fc fusion proteins or antibody conjugates enable insulin to hijack this transport pathway. However, FcRn exhibits pH-dependent binding (optimal at acidic pH 6.0-6.5, minimal at physiological pH 7.4), complicating oral delivery applications. Small molecule FcRn antagonists that modulate receptor function may enable alternative strategies. Transferrin receptor-mediated transcytosis via transferrin conjugation or antibody targeting provides additional options.

Cell-penetrating peptides (CPPs) such as TAT peptide from HIV, penetratin from Antennapedia homeobox protein, and synthetic amphipathic peptides facilitate direct membrane translocation through energy-independent and -dependent mechanisms. Conjugation of CPPs to insulin or display on nanoparticle surfaces enhances cellular uptake and transcellular transport. However, CPPs lack cell-type specificity and may enhance uptake by all cells, potentially causing off-target effects. Intestine-targeting peptides identified through phage display or rational design provide improved selectivity for enterocytes.

5.3. Lymphatic Transport Exploitation

The intestinal lymphatic system provides an alternative absorption route that bypasses hepatic first-pass metabolism, although this deviates from the goal of replicating physiological hepatoportal insulin gradients. Lipophilic compounds and large lipid particles (chylomicrons) preferentially enter mesenteric lymphatics rather than portal blood. Chemical lipidization of insulin or encapsulation in lipid nanocarriers promotes lymphatic uptake. Long-chain fatty acid conjugates, lipid prodrugs, and association with lipid absorption processes facilitate this pathway.

Lymphatic transport offers advantages of avoiding harsh hepatic enzymatic environment and achieving systemic exposure without hepatic first-pass extraction. However, lymphatic absorption rates are slower than portal absorption, lymphatic flow exhibits high inter-individual variability, and bypassing the liver eliminates the physiological advantage of preferential hepatic insulin delivery. Clinical applications may focus on basal insulin replacement where sustained release is desirable, while prandial insulin requirements would still necessitate rapid portal absorption. Hybrid formulations combining portal-absorbed rapid-acting insulin with lymphatic-absorbed sustained-release insulin represent potential strategies for complete glycemic management.

5.4. Active Efflux Transporter Inhibition

ATP-binding cassette (ABC) transporters including P-glycoprotein (P-gp/MDR1), multidrug resistance-associated proteins (MRPs), and breast cancer resistance protein (BCRP) expressed on the apical enterocyte membrane actively efflux absorbed drugs back into the intestinal lumen. While insulin as a large peptide is not a classical substrate for these transporters, co-administered excipients, permeation enhancers, or metabolites may be efflux substrates. Efflux transporter inhibition using agents such as verapamil, cyclosporine A, or various natural compounds can increase net absorption of substrate molecules.

However, systemic efflux transporter inhibition raises significant safety concerns including altered disposition of concomitant medications, increased exposure to dietary toxins normally excluded by intestinal efflux, and potential for drug-drug interactions. Localized inhibition strategies employing transporter inhibitors that are not systemically absorbed or targeting carriers to enterocyte apical surfaces while avoiding basolateral and systemic distribution may provide safer approaches. The clinical relevance of efflux transporter inhibition for insulin delivery remains uncertain given insulin's size and physicochemical properties, but consideration is warranted for comprehensive formulation optimization.

Table 4: Clinical Trials and Commercial Development of Oral Insulin Products

Product/Company	Technology Platform	Development Stage	Key Results	Bioavailability	Status
ORMD-0801 (Oramed)	Enteric coating + protease inhibitor	Phase 3	Reduced HbA1c vs placebo	~5%	Active trials ongoing
Capsulin (Diabetology)	Sodium caprate + SNAC in capsule	Phase 2	Improved glycemic control	~3-5%	Development suspended
Oshadi Icp (Oshadi Drug Admin)	Permeation enhancer technology	Phase 2	Reduced insulin requirements	~2-8%	Active development
I338 (Insulin oral spray, Generex)	Buccal spray delivery	Phase 3/Filed NDA	Rapid absorption, meal coverage	~10-15% (buccal)	FDA approval denied
HDV-Insulin (Diasome)	Hepatic-directed vesicles	Phase 2	Hepatic preferential uptake	~5-10%	Active trials
IN-105 (Biocon)	Insulin-GIPET technology	Phase 3 discontinued	Variable bioavailability	~5-12%	Development discontinued
Insulin tregopil (Novo Nordisk)	Tablet with SNAC	Phase 2 (type 2 DM)	Non-inferior HbA1c reduction	~1%	Discontinued 2019
RaniPill (Rani Therapeutics)	Robotic pill with microneedles	Phase 1	Luminal injection delivery	>50% relative to SC	Active development

6. Pharmacokinetics and Bioavailability Optimization

6.1. Absorption Kinetics and Bioavailability Benchmarks

Oral insulin bioavailability, defined as the fraction of administered dose reaching systemic circulation intact and biologically active, remains disappointingly low in most experimental systems. Conventional formulations achieve absolute bioavailability below 1%, while advanced nanotechnology systems reach 5-15% in optimized preclinical studies, still far below the approximately 100% bioavailability of subcutaneous injection. Relative bioavailability comparisons accounting for different routes of administration and first-pass metabolism provide more relevant metrics. The pharmacokinetic profile of oral insulin ideally demonstrates rapid absorption (Tmax 30-90 minutes), moderate duration of action (3-5 hours for prandial coverage), and reproducible dose-response relationships.

Factors influencing oral insulin bioavailability include formulation properties (particle size, surface chemistry, release kinetics), gastrointestinal physiology (pH, transit time, enzyme activity, mucus thickness), food effects (fed versus fasted states), and individual patient variables (intestinal disease, medications, genetic polymorphisms in transporters or enzymes). Inter-individual variability in bioavailability can exceed 50%, creating challenges for dose standardization and titration. Intra-individual variability must be minimized to less than 20-30% for acceptable day-to-day glycemic control. Bioavailability enhancement strategies must balance increased absorption against maintaining safety margins and avoiding excessive plasma insulin fluctuations that trigger hypoglycemia.

Pharmacokinetic modeling approaches including population pharmacokinetics, physiologically-based pharmacokinetic modeling, and absorption modeling facilitate rational formulation optimization and clinical dose selection. These models integrate formulation dissolution, gastrointestinal transit, metabolic degradation, absorption kinetics, and systemic disposition to predict plasma concentration-time profiles. *In vitro-in vivo* correlation studies validate model predictions and enable formulation screening without extensive animal studies. However, species differences in gastrointestinal physiology, metabolism, and insulin sensitivity complicate extrapolation from animal models to human clinical performance.

6.2. Food Effects and Administration Considerations

Food intake profoundly impacts oral insulin bioavailability through multiple mechanisms including altered gastric pH and emptying, increased intestinal enzyme secretion, competition for absorption mechanisms, and changes in splanchnic blood flow. Fat content particularly delays gastric emptying and stimulates bile secretion, potentially affecting lipid-based formulations. Protein content increases protease activity, threatening unprotected insulin. The temporal relationship between oral insulin administration and meal consumption critically influences both insulin absorption kinetics and glycemic control outcomes.

Three administration scenarios warrant consideration: fasting administration (typically 30 minutes before meals), administration with meals, and postprandial administration. Fasting administration theoretically maximizes bioavailability by minimizing food-related enzyme activity and pH alterations but requires advance planning and delays meal consumption. Administration with meals improves convenience and compliance but increases enzymatic degradation and may alter absorption kinetics. Postprandial administration aligns insulin action with peak glucose excursions but misses the critical early prandial period. Clinical formulation development must define optimal administration instructions based on product-specific pharmacokinetics and target patient populations.

Formulation strategies to minimize food effects include robust enteric coatings resistant to pH variations, high-dose formulations providing adequate absorption despite food-related losses, and modified-release profiles adjusted for fed-state transit times. Clinical development programs must include thorough fed-fasted bioavailability studies to characterize food effects and establish appropriate dosing instructions. Real-world adherence depends heavily on convenience, so formulations tolerant of various administration scenarios offer practical advantages despite potential bioavailability compromises.

6.3. Hepatic First-Pass Effect and Pharmacodynamic Considerations

Unlike subcutaneous insulin that enters peripheral circulation directly, orally absorbed insulin undergoes hepatic first-pass metabolism with 50-80% extraction during initial passage

through the liver. This substantial first-pass effect traditionally considered a liability actually represents a potential advantage for oral insulin, as it recreates the physiological hepatoportal insulin gradient present in healthy individuals with functional pancreatic beta cells. Preferential hepatic insulin exposure optimally regulates hepatic glucose output, glycogen synthesis, and gluconeogenesis while reducing peripheral hyperinsulinemia associated with subcutaneous injection.

The pharmacodynamic consequences of hepatoportal insulin delivery include improved hepatic glucose disposal, reduced hepatic glucose production, decreased peripheral insulin exposure with potentially less weight gain and lipogenesis, and better replication of physiological insulin secretion patterns. Clinical studies must evaluate whether these theoretical advantages translate to superior glycemic control, reduced hypoglycemia, improved weight profiles, or better long-term outcomes compared to subcutaneous insulin. Glucose clamp studies, meal tolerance tests, and tracer studies quantifying hepatic versus peripheral insulin action provide mechanistic insights.

Optimizing the hepatic/peripheral insulin exposure ratio through formulation design enables tailoring of metabolic effects. Formulations promoting rapid portal absorption create high hepatic extraction and maximal hepatoportal gradient, suitable for prandial coverage. Systems with slower, sustained absorption achieve more balanced hepatic/peripheral distribution appropriate for basal insulin replacement. Combination products or regimens employing different oral formulations for prandial and basal needs may ultimately prove most effective for comprehensive glycemic management.

7. Safety and Toxicology Considerations

7.1. Local Gastrointestinal Toxicity

Chronic oral insulin administration raises concerns regarding potential local gastrointestinal toxicity from insulin itself or, more likely, from formulation excipients including permeation enhancers, protease inhibitors, or nanoparticle materials. Intestinal epithelial integrity must be maintained to prevent bacterial translocation, inflammatory responses, or compromised absorption of essential nutrients. Repeated exposure to permeation enhancers that transiently open tight junctions could theoretically cause cumulative damage, chronic inflammation, or adaptive changes in barrier function. However, properly designed reversible enhancers should exhibit complete recovery between doses with no residual effects.

Preclinical toxicology programs must include dose-escalation studies, chronic administration studies (3-6 months minimum), histopathological examination of intestinal tissues, assessment of inflammatory biomarkers, evaluation of intestinal microbiome impacts, and functional assays of nutrient absorption. Comparison groups receiving subcutaneous insulin control for diabetes-related intestinal changes versus formulation-induced toxicity. Special attention to sensitive populations including patients with inflammatory bowel disease, celiac disease, or other gastrointestinal disorders is warranted. Clinical monitoring strategies may include periodic fecal calprotectin measurements, intestinal permeability assessments, and colonoscopic surveillance in select cases.

Nanoparticle materials require particular scrutiny regarding accumulation, biodegradation, and long-term safety. While polymers like PLGA and chitosan have established safety profiles, chronic high-dose exposure in diabetes patients differs from acute or intermittent use in other applications. Inorganic materials raise additional concerns about persistence and potential toxicity. Material characterization, biodistribution studies, and long-term accumulation studies in relevant animal models are essential prerequisites for clinical development. Regulatory guidance documents for nanomedicines provide frameworks for safety assessment but require adaptation for oral chronic disease applications.

7.2. Systemic Safety and Immunogenicity

Oral insulin delivery theoretically reduces immunogenicity compared to subcutaneous injection by inducing oral tolerance through gastrointestinal immune system exposure. However, formulation components, particularly nanoparticles and permeation enhancers that facilitate absorption, may bypass normal tolerance-inducing mechanisms and instead trigger inappropriate immune responses. Chemical modifications of insulin (PEGylation, acylation, conjugation to targeting ligands) create neo-epitopes potentially recognized as foreign by the immune system. Aggregated or denatured insulin exhibits enhanced immunogenicity compared to native monomeric hormone.

Preclinical immunogenicity assessment includes measurement of anti-insulin antibodies (IgG, IgE, IgA isotypes), evaluation of T-cell responses, and assessment of allergic or anaphylactic potential. Chronic dosing studies in relevant species must extend sufficiently to capture delayed immune responses. Clinical immunogenicity monitoring requires sensitive, validated assays for anti-drug antibodies and correlation of antibody titers with clinical outcomes including glycemic control, insulin dose requirements, and adverse events. While anti-insulin antibodies are common in insulin-treated diabetes patients, high-titer neutralizing antibodies that impair glycemic control or cause hypersensitivity reactions represent safety concerns requiring product discontinuation.

Oral tolerance induction represents a potential therapeutic advantage where properly designed oral insulin formulations might reduce rather than increase immunogenicity. Some preclinical studies suggest that oral insulin administration can suppress autoimmune responses in type 1 diabetes, though clinical trials of oral insulin for diabetes prevention have shown mixed results. Future formulations might deliberately optimize for tolerogenic rather than immunogenic presentation, potentially offering dual benefits of therapeutic efficacy and immune modulation.

7.3. Hypoglycemia Risk and Glycemic Variability

Hypoglycemia represents the primary safety concern for any insulin therapy, with severe hypoglycemic events causing seizures, loss of consciousness, cardiovascular complications, and death. Oral insulin formulations with unpredictable or highly variable absorption create unacceptable hypoglycemia risk, particularly if patients cannot accurately predict insulin action timing and intensity. The ideal oral insulin demonstrates consistent, reproducible pharmacokinetics with narrow variability enabling reliable dose titration. Meal-related administration helps minimize hypoglycemia risk by ensuring glucose availability during insulin action periods.

The slower absorption kinetics of most oral insulin formulations compared to rapid-acting subcutaneous analogs

may reduce hypoglycemia risk by creating more gradual plasma insulin increases. Conversely, delayed absorption combined with repeated dosing due to perceived lack of effect could cause dangerous insulin stacking and late hypoglycemia. Patient education regarding appropriate dosing, timing, and recognition of hypoglycemia symptoms becomes even more critical with oral administration where injection visibility is lost. Continuous glucose monitoring systems facilitate safe oral insulin titration and help detect patterns of variability requiring dose adjustment.

Clinical development programs must carefully evaluate hypoglycemia incidence, severity, and risk factors across diverse patient populations and usage scenarios. Glucose clamp studies provide controlled assessment of hypoglycemic thresholds and counterregulatory responses. Real-world studies capture the full spectrum of hypoglycemia risk in typical practice conditions. Risk mitigation strategies may include conservative initial dosing, gradual titration protocols, combination with continuous glucose monitoring, and clear instructions for managing delayed or unpredictable insulin action.

8. Clinical Development and Regulatory Pathways

8.1. Phase 1 and Phase 2 Clinical Studies

Early-phase clinical development of oral insulin products begins with Phase 1 studies in healthy volunteers establishing safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics. Single ascending dose studies define the dose range for subsequent testing, identify dose-limiting toxicities, and characterize absorption profiles. Multiple ascending dose studies evaluate accumulation potential, steady-state pharmacokinetics, and safety upon repeated administration. Fed-fasted bioavailability studies characterize food effects critical for ultimate dosing instructions. Glucose clamp studies in healthy volunteers provide controlled assessment of insulin action independent of endogenous insulin secretion variations.

Phase 2 studies in patients with type 1 or type 2 diabetes evaluate efficacy endpoints including HbA1c reduction, fasting and postprandial glucose control, insulin dose requirements, and hypoglycemia incidence. Study designs may employ add-on therapy to existing regimens, partial replacement of subcutaneous insulin, or complete replacement depending on formulation characteristics and target indication. Dose-ranging studies identify the optimal dose or dose range for Phase 3 development. Biomarker studies assess hepatic versus peripheral insulin action through measurements of hepatic glucose production, peripheral glucose uptake, and lipid metabolism.

Critical decisions in early clinical development include selection of target population (type 1 versus type 2 diabetes, insulin-naïve versus insulin-experienced), choice of comparator (placebo, subcutaneous insulin, oral hypoglycemics), and definition of appropriate efficacy and safety endpoints. The high bar for efficacy (non-inferiority or superiority to subcutaneous insulin) and safety (hypoglycemia rates no worse than subcutaneous) challenges oral insulin development. Adaptive trial designs allowing dose optimization or population enrichment based on interim analyses can improve development efficiency.

8.2. Phase 3 Pivotal Trials and Regulatory Submission

Phase 3 pivotal trials provide definitive evidence of efficacy and safety to support regulatory approval and product labeling. Non-inferiority designs comparing oral insulin to subcutaneous insulin or oral hypoglycemic agents in type 2 diabetes represent common regulatory strategies. Study durations typically extend 24-52 weeks to adequately assess HbA1c changes and safety. Primary endpoints focus on HbA1c reduction, with secondary endpoints including fasting plasma glucose, postprandial glucose, hypoglycemia rates, weight changes, and quality of life measures. Safety assessments emphasize hypoglycemia, gastrointestinal adverse events, immunogenicity, and cardiovascular safety.

Regulatory requirements vary across jurisdictions but generally align with guidance documents for diabetes drugs emphasizing cardiovascular safety, hypoglycemia risk assessment, and long-term safety. The novel delivery route and complex formulations of oral insulin products raise additional regulatory considerations regarding manufacturing consistency, product characterization, stability, and quality control. Demonstration of batch-to-batch consistency, shelf-life stability, and absence of functionally significant variations between clinical and commercial manufacturing scales is essential for approval.

Post-approval commitments typically include long-term safety studies, real-world effectiveness studies, and pharmacovigilance programs monitoring for rare adverse events. Pediatric development programs address the substantial unmet need for needle-free insulin delivery in children, though pediatric trials generally follow adult approval. Regulatory pathways for novel drug-device combination products (such as robotic pills) involve additional complexity requiring coordination between drug and device review divisions and compliance with both pharmaceutical and device regulatory frameworks.

8.3. Manufacturing, Quality Control, and ommercialization

Manufacturing of oral insulin products presents substantial technical challenges requiring robust, scalable processes with stringent quality control. Insulin stability during formulation, aseptic processing requirements, prevention of aggregation and denaturation, and maintenance of biological activity throughout shelf-life demand sophisticated pharmaceutical development. Nanoparticle formulations require reproducible particle size distributions, drug loading uniformity, and colloidal stability. Excipient quality and consistency critically influence product performance and safety.

Analytical methods for product characterization must assess insulin content and potency, structural integrity, aggregation state, nanoparticle characteristics (size, charge, morphology), release kinetics, and microbiological quality. Stability studies under various storage conditions (temperature, humidity, light) define shelf-life and guide packaging selection. Cold chain requirements similar to subcutaneous insulin may be necessary unless formulations achieve room-temperature stability through lyophilization, solid dosage forms, or stabilizing excipients.

Commercialization considerations include manufacturing costs, pricing strategies, reimbursement negotiations, and market positioning relative to established insulin products. The convenience premium of oral delivery may justify higher costs, but price-sensitive markets and cost-effectiveness requirements from payers constrain pricing flexibility. Manufacturing economies of scale, patent protection, regulatory exclusivity, and competitive dynamics influence

commercial viability. Market access strategies must address different healthcare systems, diabetes treatment practices, and patient populations across global markets.

9. Future Directions and Emerging Technologies

9.1. Smart and Responsive Delivery Systems

Next-generation oral insulin systems incorporate stimuli-responsive capabilities enabling glucose-responsive insulin release, self-regulating feedback control, and personalized delivery kinetics. Glucose-sensitive materials including phenylboronic acid derivatives, glucose oxidase-based systems, and concanavalin A-glycogen complexes modulate insulin release in response to glucose concentrations. These "closed-loop" oral delivery systems aim to reduce hypoglycemia risk and improve glycemic stability compared to fixed-dose formulations. However, achieving appropriate sensitivity, response kinetics, and physiological glucose sensing in the gastrointestinal environment presents significant challenges.

Enzyme-triggered systems exploit diabetes-associated alterations in gastrointestinal enzyme expression or activity to modulate insulin release. Multi-stimuli responsive systems combining pH, enzyme, and redox-sensitive components enable sophisticated staged release profiles matched to gastrointestinal transit and physiological states. However, increased complexity raises manufacturability concerns and regulatory questions regarding reproducibility and quality control. Practical implementation likely requires balance between sophistication and reliability, with incremental rather than revolutionary advances more feasible in near-term products.

Integration of oral insulin delivery with digital health technologies including smartphone applications, artificial intelligence-based dose optimization, and integration with continuous glucose monitoring systems represents an important future direction. Machine learning algorithms can identify individual patient absorption patterns, predict optimal dosing timing, and provide real-time guidance. However, digital health integration must enhance rather than complicate user experience, with intuitive interfaces accessible to diverse patient populations including elderly and technology-averse individuals.

9.2. Alternative Oral Delivery Devices and Approaches

Innovative device-based approaches transcend conventional formulation strategies through physical means of overcoming gastrointestinal barriers. The RaniPill system employs an ingestible robotic capsule containing compressed insulin powder and spring-loaded microneedles that inject insulin directly into the intestinal wall upon pH-triggered activation. This approach achieves bioavailability exceeding 50% relative to subcutaneous injection by bypassing enzymatic degradation and epithelial barriers. However, patient acceptance of mechanical injection devices, manufacturing complexity, cost, and safety of repeated intestinal wall penetration require careful evaluation.

Ultrasound-mediated delivery employs ingested capsules containing ultrasound transducers that transiently enhance intestinal permeability through cavitation and mechanical effects, facilitating insulin absorption from co-administered or capsule-contained formulations. Electromagnetic field-responsive systems use external magnetic fields to guide and activate drug-releasing capsules or particles at specific gastrointestinal locations. These sophisticated approaches require extensive engineering development, regulatory navigation as combination products, and assessment of patient acceptance and long-term safety.

Buccal and sublingual delivery, though technically distinct from true oral delivery, offer needle-free alternatives with rapid absorption and avoidance of gastrointestinal degradation. Buccal formulations employing mucoadhesive patches or sprays achieve bioavailability of 10-20% but require patient cooperation in avoiding swallowing and may cause local irritation. Pulmonary insulin delivery (inhaled insulin) achieved FDA approval but failed commercially due to patient acceptance issues, highlighting that clinical efficacy alone is insufficient without addressing practical usability and patient preferences.

9.3. Personalized and Precision Oral Insulin Therapy

Pharmacogenomic approaches identify genetic variations influencing oral insulin absorption, metabolism, and action, enabling personalized formulation selection and dose optimization. Polymorphisms in genes encoding drug transporters, metabolic enzymes, insulin receptors, and glucose homeostasis regulators may explain inter-individual variability in oral insulin response. Companion diagnostics could guide patient selection for oral insulin therapy, identify individuals likely to achieve adequate bioavailability, and predict optimal dosing regimens. However, the cost and complexity of pharmacogenomic testing must be justified by substantial improvements in outcomes.

Patient phenotyping based on gastrointestinal physiology, diabetes characteristics, lifestyle factors, and treatment history can inform personalized treatment algorithms. Factors including gastric pH, intestinal transit time, enzyme activity, gut microbiome composition, dietary patterns, and concurrent medications influence oral insulin performance. Real-world data analytics and machine learning applied to large patient datasets may identify predictive patterns enabling algorithmic dose optimization. However, accessibility, equity, and avoidance of excessive medical complexity remain important considerations.

The future optimal diabetes management paradigm may involve combination approaches employing oral insulin for basal and/or prandial coverage, continuous glucose monitoring for feedback, subcutaneous insulin pumps as backup or supplementation, and integration with artificial pancreas algorithms. Rather than complete replacement of subcutaneous delivery, oral insulin may find optimal use in hybrid regimens leveraging complementary advantages of different delivery routes. Patient preferences, individual metabolic characteristics, and lifestyle considerations guide personalized treatment selection from an expanding menu of options.

10. Conclusion

Oral insulin delivery represents a transformative goal in diabetes therapeutics with profound implications for patient quality of life, treatment adherence, clinical outcomes, and global health equity. Despite nearly a century of research, the formidable gastrointestinal barriers of acidic pH, enzymatic degradation, mucus layer impedance, and epithelial impermeability continue to limit oral insulin bioavailability to levels substantially below subcutaneous injection. Nevertheless, sustained advances in pharmaceutical sciences, nanotechnology, materials science, and biomedical engineering have yielded increasingly sophisticated delivery

systems demonstrating clinical promise.

Contemporary oral insulin formulations employ multi-faceted strategies combining enteric protection, protease inhibition, permeation enhancement, nanoparticle encapsulation, and receptor-mediated targeting to achieve bioavailability of 5-15% in optimized preclinical systems, with some clinical candidates demonstrating therapeutic efficacy despite modest absolute bioavailability. The physiological advantages of hepatoportal insulin delivery partially compensate for reduced bioavailability, potentially providing superior metabolic regulation compared to peripheral subcutaneous injection at equivalent glycemic control. However, significant challenges remain regarding reproducibility, stability, manufacturing scalability, safety upon chronic administration, and cost-effectiveness relative to established insulin products.

Clinical development of oral insulin has progressed with multiple products reaching Phase 2 and Phase 3 trials, though several programs have been discontinued due to insufficient efficacy, unacceptable variability, or commercial considerations. Recent regulatory approval of oral semaglutide for type 2 diabetes demonstrates the feasibility of oral peptide delivery and provides valuable precedents for oral insulin development, though semaglutide's weekly dosing and higher tolerable variability differ substantially from insulin's requirements. Ongoing trials and emerging technologies including sophisticated nanoparticle systems, device-based delivery, and glucose-responsive formulations continue advancing toward the long-sought goal of effective, safe, convenient needle-free insulin therapy.

The path forward requires integrated efforts spanning fundamental research on gastrointestinal physiology and insulin absorption mechanisms, innovative formulation and device engineering, rigorous preclinical safety evaluation, well-designed clinical trials demonstrating superiority or non-inferiority to current standards, and realistic assessment of commercial viability and patient acceptance. Success will likely emerge from incremental advances rather than single breakthrough technologies, with practical products balancing performance optimization against manufacturing feasibility, safety assurance, regulatory approval, and market accessibility. Ultimately, achieving clinically viable oral insulin delivery will transform diabetes management for millions of patients worldwide, reducing treatment burden while improving health outcomes and quality of life.

11. References

1. Sun H, Saeedi P, Karuranga S, *et al*. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.
2. American Diabetes Association Professional Practice Committee. Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. doi:10.2337/dc24-SINT.
3. Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16. doi:10.2337/dc13-2112.
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2024;47(1):26-43. doi:10.2337/dci23-0085.
5. Kahanovitz L, Sluss PM, Russell SJ. Type 1 diabetes—a clinical perspective. Point Care. 2017;16(1):37-40. doi:10.1097/POC.0000000000000129.
6. Edgerton DS, Cherrington AD. Is brain insulin action relevant to the control of plasma glucose in humans? Diabetes. 2015;64(3):696-699. doi:10.2337/db14-1816.
7. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689. doi:10.1111/j.1464-5491.2012.03605.x.
8. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016;4(3):275-285. doi:10.1016/S2213-8587(15)00521-5.
9. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728-742. doi:10.1177/193229681200600402.
10. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Technol. 2009;3(3):562-567. doi:10.1177/193229680900300322.
11. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13(9):923-954. doi:10.2337/diacare.13.9.923.
12. Fonte P, Araújo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol. 2013;7(2):520-531. doi:10.1177/193229681300700228.
13. Sonia TA, Sharma CP. An overview of natural polymers for oral insulin delivery. Drug Discov Today. 2012;17(13-14):784-792. doi:10.1016/j.drudis.2012.03.019.
14. Dressman JB, Berardi RR, Dermentzoglou LC, *et al*. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756-761. doi:10.1023/A:1015827908309.
15. Goldman J, Carpenter FH. Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives. Biochemistry. 1974;13(22):4566-4574. doi:10.1021/bi00719a015.
16. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci. 1997;86(5):517-525. doi:10.1021/js960297s.
17. Iyer H, Khedkar A, Verma M. Oral insulin—a review of current status. Diabetes Obes Metab. 2010;12(3):179-185. doi:10.1111/j.1463-1326.2009.01150.x.
18. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):153-214. doi:10.1615/CritRevTherDrugCarrierSyst.v20.i23.30.
19. Erickson RH, Kim YS. Digestion and absorption of dietary protein. Annu Rev Med. 1990;41:133-139. doi:10.1146/annurev.me.41.020190.001025.
20. Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007;59(15):1521-1546. doi:10.1016/j.addr.2007.08.019.